6th Street Advisors LLC Purchases 5,848 Shares of Danaher Corporation $DHR

6th Street Advisors LLC bought a new stake in shares of Danaher Corporation (NYSE:DHR) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 5,848 shares of the conglomerate’s stock, valued at approximately $1,296,000. Danaher accounts for 0.7% of 6th Street Advisors LLC’s portfolio, making the stock its 16th biggest position.

Several other institutional investors have also modified their holdings of the business. BlackRock Inc. acquired a new position in Danaher in the 2nd quarter valued at $10,492,520,000. Wellington Management Group LLP lifted its holdings in Danaher by 10.4% in the second quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock valued at $3,108,031,000 after acquiring an additional 1,542,310 shares during the period. Jupiter Topco LLC purchased a new position in shares of Danaher in the 2nd quarter valued at about $1,456,317,000. Generation Investment Management LLP acquired a new stake in shares of Danaher in the second quarter valued at about $1,287,949,000. Finally, Bank of America Corp DE purchased a new stake in Danaher during the second quarter worth about $993,846,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE DHR traded up $1.19 during trading hours on Wednesday, reaching $224.03. The company’s stock had a trading volume of 1,890,805 shares, compared to its average volume of 4,448,106. The stock has a market cap of $157.49 billion, a PE ratio of 39.79, a PEG ratio of 2.78 and a beta of 0.76. The business has a 50-day simple moving average of $212.41 and a 200 day simple moving average of $195.13. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR) last released its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.77 EPS. Equities research analysts predict that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio is presently 28.42%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Evercore reissued an “outperform” rating and set a $230.00 price target on shares of Danaher in a research report on Monday, July 6th. Morgan Stanley boosted their price target on Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a report on Monday. Weiss Ratings raised Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. Guggenheim upped their price target on shares of Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Finally, TD Cowen boosted their price objective on shares of Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a research note on Tuesday. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average target price of $235.41.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced a collaboration combining Danaher’s scientific instruments, laboratory workflows, automation technologies and data with NVIDIA’s accelerated computing and AI capabilities. The companies aim to advance autonomous science and speed up research, potentially creating new growth opportunities in life-science tools. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is reportedly preparing to launch its first AI-powered autonomous laboratory, expected to operate at commercial scale in early 2027. The initiative could support demand for Danaher’s instruments, software and laboratory automation offerings as AI adoption expands. How to Invest in AI Drug Discovery
• Positive Sentiment: Zacks said Danaher has two indicators associated with a potential earnings beat ahead of its upcoming report. A stronger-than-expected result could reinforce investor confidence following the company’s previous quarterly beat on revenue and earnings. Danaher Earnings Expected to Grow
• Positive Sentiment: Morgan Stanley maintained its $240 price target for DHR, signaling continued confidence in the stock’s outlook and leaving room for further appreciation based on the referenced trading level. Morgan Stanley Keeps $240 Target for Danaher
• Neutral Sentiment: Danaher appointed Daniel L. Comas and Robert Hershberg to its board, expanding it to 13 members. The appointments may strengthen governance and industry expertise but are unlikely to materially affect near-term trading. Danaher Announces Board Appointments

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.